£129.99

It has never been this cheap. We have no record of a lower price.

£130 today · cheaper than every other day in the last 3 months

Springer Gene and Cell Therapies for Beta-Globinopathies: 1013 (American Society of Gene & Cell Therapy)

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 25 days · 25 data points (no recent data)

Historical
Generating forecast…
£129.99 £123.49 £126.09 £128.69 £131.29 £133.89 £136.49 22 August 2026 28 August 2026 03 September 2026 09 September 2026 15 September 2026
View at Amazon ↗

Price data last checked 66 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 25 days • 1 price levels

Days at Price
25 days 0 6 13 19 25 £130 Days at Price

Price Analysis

Most common price: £130 (25 days, 100.0%)

Price range: £130 - £130

Price levels: 1 different prices over 25 days

Description

Hemoglobin defects, specifically sickle cell disease & thalassemia, combined, constitute the most common monogenic disorders in the world. In fact, nearly 2% of the world’s population carries a globin gene mutation. The transfer of the corrective globin gene through the HSC compartment by allogeneic HSC transplantation (HSCT) has already proven curative in both SCD and thalassemia patients, and provides the proof of concept that genetic manipulation of the defective organ might be equally therapeutic. However, procedural toxicities and the requirement of an HLA-matched sibling donor limit this approach to a fraction of affected individuals. The editors review the progress & the state of the field in HSCT for hemoglobinopathies & shed light on the major changes expected in the next decade. Although allogeneic HSCT is a curative option, it is limited by the availability of matched donors, which are often available only to 15-20% of patients. An alternative to allogeneic HS CT is genetic correction of autologous HSCs, to overcome donor availability & immune side effects. This Book reviews the progress made on additive gene therapy approaches & the current state of the field. Finally, targeted genetic correction is emerging as a novel therapeutic strategy in the hemoglobinopathies. Although ideal, the inefficiency of targeted correction was rate limiting for translation of this technology to the clinic. With advancements in zinc finger nucleases and TALE endonuclease mediated targeted correction, correction frequencies in hematopoietic stem cells is now reaching levels that may become clinically relevant. Furthermore, the ability to generate autologous embryonic stem cell like cells from primary somatic cells (skin fibroblasts or hematopoietic cells) of the affected individual has allowed for the potential application of genetic correction strategies.This Book reviews upcoming genetic strategies to reactivate fetal hemoglobin production and research advances.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
28 August 2018
Listed Since
31 August 2018

Barcode

No barcode data available

Similar Products You Might Like

Sickle Cell Disease and Hematopoietic Stem Cell Transplantation
84% match

Sickle Cell Disease and Hematopoietic Stem Cell Transplantation

Springer

£65.61 24 Oct 2026
Sickle Cell Disease and Hematopoietic Stem Cell Transplantation
84% match

Sickle Cell Disease and Hematopoietic Stem Cell Transplantation

Springer

£92.00 16 Sep 2026
Blood Cell Biochemistry: Hematopoiesis and Gene Therapy: 8
82% match

Blood Cell Biochemistry: Hematopoiesis and Gene Therapy: 8

Springer

£113.93 27 Oct 2026
Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics
79% match

Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics

Springer

£108.91 15 Sep 2026
Cooley's Anemia: Ninth Symposium, Volume 1202 (Annals of the New York Academy of Sciences)
79% match

Cooley's Anemia: Ninth Symposium, Volume 1202 (Annals of the New York Academy of Sciences)

Wiley

£89.98 14 Nov 2026
Non-Neoplastic Hematologic Disorders: A Quick Review of Modern Diagnostic and Therapeutic Approaches
79% match

Non-Neoplastic Hematologic Disorders: A Quick Review of Modern Diagnostic and Therapeutic Approaches

Springer

£103.27 20 Oct 2026
Advances in Hematopoietic Stem Cell Transplantation and Molecular Therapy: 144 (Recent Results in Cancer Research, 144)
79% match

Advances in Hematopoietic Stem Cell Transplantation and Molecular Therapy: 144 (Recent Results in Cancer Research, 144)

Springer

£78.01 14 Sep 2026
Muscle Gene Therapy
78% match

Muscle Gene Therapy

Springer

£129.99 24 Oct 2026
Myelodysplastic Syndromes: Diagnosis - Prognosis - Therapy (Hematologic Malignancies)
78% match

Myelodysplastic Syndromes: Diagnosis - Prognosis - Therapy (Hematologic Malignancies)

Springer

£73.14 17 Oct 2026
Genome Editing: The Next Step in Gene Therapy: 895 (Advances in Experimental Medicine and Biology, 895)
78% match

Genome Editing: The Next Step in Gene Therapy: 895 (Advances in Experimental Medicine and Biology, 895)

Springer

£100.11 22 Oct 2026
Gene-Based Therapies for Cancer (Current Cancer Research)
77% match

Gene-Based Therapies for Cancer (Current Cancer Research)

Springer

£110.00 23 Oct 2026
Iron Chelation Therapy: 509 (Advances in Experimental Medicine and Biology, 509)
77% match

Iron Chelation Therapy: 509 (Advances in Experimental Medicine and Biology, 509)

Springer

£75.91 21 Oct 2026
Benign Hematologic Disorders in Children: A Clinical Guide
77% match

Benign Hematologic Disorders in Children: A Clinical Guide

Springer

£97.06 14 Nov 2026
Human Gene Therapy: Current Opportunities and Future Trends: 43 (Ernst Schering Foundation Symposium Proceedings, 43)
77% match

Human Gene Therapy: Current Opportunities and Future Trends: 43 (Ernst Schering Foundation Symposium Proceedings, 43)

Springer

£164.34 03 Nov 2026
Human Fetal Tissue Transplantation
77% match

Human Fetal Tissue Transplantation

Springer

£96.57 16 Sep 2026
Erythropoiesis/Hematopoiesis: Volume 170 (Current Topics in Developmental Biology, Volume 170)
77% match

Erythropoiesis/Hematopoiesis: Volume 170 (Current Topics in Developmental Biology, Volume 170)

Elsevier

£128.00 21 Oct 2026
Nonmalignant Hematology: Expert Clinical Review: Questions and Answers
76% match

Nonmalignant Hematology: Expert Clinical Review: Questions and Answers

Springer

£169.35 20 Oct 2026
Gene Therapy in Reconstructive and Regenerative Surgery
76% match

Gene Therapy in Reconstructive and Regenerative Surgery

Springer

£77.23 03 Nov 2026
Haematology
76% match

Haematology

McGraw-Hill Education

£86.50 14 Nov 2026
Wiley-Blackwell Hematology: 101 Morphology Updates Book
76% match

Wiley-Blackwell Hematology: 101 Morphology Updates Book

Wiley

£38.08 26 Oct 2026
Genetic Modification of Hematopoietic Stem Cells: Methods and Protocols: 506 (Methods in Molecular Biology, 506)
76% match

Genetic Modification of Hematopoietic Stem Cells: Methods and Protocols: 506 (Methods in Molecular Biology, 506)

Humana

£73.87 14 Sep 2026
Molecular Biology of Hematopoiesis 6
76% match

Molecular Biology of Hematopoiesis 6

Springer

£165.01 25 Oct 2026
Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies (Advances in Blood Disorders, 2)
76% match

Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies (Advances in Blood Disorders, 2)

Routledge

£94.99 22 Oct 2026
Advances in Transfusion Medicine: A Practical Handbook
76% match

Advances in Transfusion Medicine: A Practical Handbook

Elsevier

£150.09 21 Oct 2026